SLN
Silence Therapeutics plc6.27
-0.33-5%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
296.16MP/E (TTM)
-Basic EPS (TTM)
-1.35Dividend Yield
0%Recent Filings
8-K
Q4 results: divesiran on track
Silence Therapeutics reported Q4 and full-year 2025 results on March 5, 2026, with cash at $85.1M but collaboration revenue plunging to $0.6M from $43.3M amid $88.6M net loss. Divesiran Phase 2 SANRECO trial accelerated; topline data now due Q3 2026. AstraZeneca dropped SLN312 post-Phase 1. Cash burn pressures pipeline optionality.
10-K
FY2025 results
Silence Therapeutics posted FY2025 ended December 31, 2025 results amid ongoing clinical momentum, with no revenue from product sales as a pre-commercial biotech and a history of net losses expected to persist. Q4 saw pipeline advances including completion of zerlasiran Phase 3 readiness activities like manufacturing scale-up, while divesiran's SANRECO Phase 2 trial reached full enrollment with topline data eyed for Q3 2026. AstraZeneca returned global rights to SLN312 post-Phase 1 in March 2026. Cash position supports operations into 2028. Pipeline unproven. We rely heavily on third parties for manufacturing and development.
8-K
CFO Hellums joins Board
8-K
CEO exits; interim leader named
Silence Therapeutics' CEO Craig Tooman stepped down by mutual consent effective December 14, 2025, after serving since 2022. Chairman Iain Ross steps in as interim principal executive officer; James Ede-Golightly rejoins the board immediately. Separation and compensation terms pending. Leadership shifts while company affirms robust financial and operational health.
10-Q
Q3 FY2025 results
Silence Therapeutics posted Q3 revenue of $0.2M, down sharply y/y from $1.5M amid lighter AstraZeneca collaboration activity, while YTD revenue fell to $0.5M from $18.0M (no milestones vs $10M prior year). R&D costs ticked up 2% q/q to $20.5M on proprietary programs like divesiran Phase 2, driving operating loss to $26.2M (better than $30.0M y/y) and net loss to $21.0M or $(0.15) per share, confirmed vs 142M diluted shares. Cash burned $45.0M in operations (no capex for FCF), leaving $102.2M in cash/short-term investments at September 30, 2025—enough into 2028 with milestones. Restructuring trimmed $1.3M YTD. Cash lasts years. Evolving data privacy laws pose compliance risks.
IPO
Employees
Sector
Industry
ALNY
Alnylam Pharmaceuticals, Inc.
391.17-0.33
ARWR
Arrowhead Pharmaceuticals, Inc.
64.66-3.79
DNLI
Denali Therapeutics Inc.
17.02-0.32
LENZ
LENZ Therapeutics, Inc.
16.70-0.38
SION
Sionna Therapeutics, Inc.
42.89+0.13
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
SLXN
Silexion Therapeutics Corp
2.61+0.05
SRPT
Sarepta Therapeutics, Inc.
22.31+0.76
VRNA
Verona Pharma plc
106.91+0.00
WVE
Wave Life Sciences Ltd.
16.41+0.30